Skip to content
Clinical Trial Events
The Liver Meeting 2026

Talk Patient Programming track

Metabolic Dysfunction–Associated Steatotic Liver Disease and Glucagon-like Peptide-1 Drugs: What Patients Want to Know

Sat, Nov 7, 2026 · 2:00–3:30 PM MST Convention Center: Mile High Ballroom 4DEF, Colorado Convention Center

About this session

Glucagon-like peptide-1 (GLP-1) drugs—including both GLP-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide [GIP] receptor agonists—have become ubiquitous in the public arena. These drugs represent some of the most promising treatment options for persons with metabolic dysfunction–associated steatohepatitis (MASH) because they treat the underlying comorbidities (obesity and diabetes) as well as MASH. Additionally, they have proven cardiovascular benefits.

Speakers